Mission Wealth Management LP Acquires 26 Shares of Eli Lilly and Company (NYSE:LLY)

Mission Wealth Management LP grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,213 shares of the company’s stock after purchasing an additional 26 shares during the quarter. Mission Wealth Management LP’s holdings in Eli Lilly and Company were worth $4,204,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of LLY. PDS Planning Inc boosted its stake in Eli Lilly and Company by 1.7% in the 3rd quarter. PDS Planning Inc now owns 4,975 shares of the company’s stock worth $2,672,000 after purchasing an additional 83 shares during the period. Boyd Watterson Asset Management LLC OH boosted its holdings in Eli Lilly and Company by 1.5% in the third quarter. Boyd Watterson Asset Management LLC OH now owns 12,141 shares of the company’s stock worth $6,521,000 after acquiring an additional 180 shares in the last quarter. Cavalier Investments LLC boosted its holdings in Eli Lilly and Company by 67.8% in the third quarter. Cavalier Investments LLC now owns 3,881 shares of the company’s stock worth $2,085,000 after acquiring an additional 1,568 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Eli Lilly and Company by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 337,104 shares of the company’s stock worth $181,069,000 after purchasing an additional 7,254 shares during the period. Finally, LFA Lugano Financial Advisors SA purchased a new position in Eli Lilly and Company during the third quarter valued at approximately $60,000. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LLY. Citigroup boosted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Morgan Stanley raised their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $731.55.

Eli Lilly and Company Stock Up 6.0 %

Shares of NYSE:LLY traded up $43.90 during trading on Tuesday, reaching $781.10. 7,428,656 shares of the stock traded hands, compared to its average volume of 3,071,009. The stock has a 50-day moving average of $760.89 and a two-hundred day moving average of $668.00. Eli Lilly and Company has a 52-week low of $392.26 and a 52-week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market cap of $742.17 billion, a P/E ratio of 134.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.09 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.